BioSpace News Archive

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer, Sc.D., as Chairman of its Scientific Advisory Board.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences. Under the terms of the February 2, 2021 stock purchase agreement, Coherus has received $50 million from Junshi Biosciences’ acquisition of 2,491,988 shares at a price per share of $20.06.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release first quarter financial and operating results prior to market open on Tuesday, May 4, 2021.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces new enabling technologies for its INTELLIO™ Connected Tower Solution with the introduction of the DOUBLEFLO™ Inflow/Outflow Pump* and 4KO™ (Optimized) Arthroscopes and Laparoscopes.

On April 10th, leading manufacturer of medical and aesthetic lasers and light source technologies, Sciton Inc., hosted over 650 medical professionals at its 2021 Rockstars of Aesthetics Virtual Summit.

More than 14 abstracts, including new findings from Incyte’s clinical trial programs for ruxolitinib cream in patients with vitiligo and atopic dermatitis, to be presented

Partnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate

Ripple Therapeutics Corporation a clinical stage, ophthalmology-focused developer of novel pharmaceuticals, announced today that the first patient has been treated in RIPPLE-1, a Phase II trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting inflammatory retinal diseases.

Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company’s MF59 ® adjuvanted, trivalent influenza vaccine (aTIV) in the peer-reviewed medical journal Clinical Infectious Diseases .

Castle Creek Biosciences, Inc. (the “Company”), today announced that Matthew Gantz has been appointed President and Chief Executive Officer.